Evidence map›Paper›PMID 27661436›Full record

ArticleJournal of pharmaceutical and biomedical analysis2016

HPLC method development, validation, and impurity characterization of a potent antitumor nucleoside, T-dCyd (NSC 764276).

Mingtao Liu, Jennie Wang, Paul Liu

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Journal of pharmaceutical and biomedical analysis, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed.

  1. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

3 authors.

Mingtao LiuSRI International, 333 Ravenswood Avenue, Menlo Park, CA, 94025, USA.
Jennie WangSRI International, 333 Ravenswood Avenue, Menlo Park, CA, 94025, USA. Electronic address: jennie.wang@sri.com.
Paul LiuPharmaceutical Resources Branch, DCTD, NCI, 9609 Medical Center Drive, Bethesda, MD, 20892, USA. Electronic address: liup@dtpepn.nci.nih.gov.

Funding

NCI NIH HHS HHSN261201200028CNCI NIH HHS HHSN261201200028I
6 · The paper itself

Abstract

An HPLC method for the assay of an anticancer nucleoside, 4'-thio-2'-deoxycytidine (T-dCyd, NSC 764276), has been developed and validated. The stress testing of T-dCyd was carried out in accordance with ICH guidelines Q1A (R2) under acidic, alkaline, oxidative, thermolytic, and photolytic conditions. The separation of T-dCyd from its impurities and degradation products was achieved in 40min on a Luna

Indexed as

Drug ContaminationAntineoplastic AgentsChromatography, High Pressure LiquidChromatography, LiquidDeoxycytidineReproducibility of ResultsTandem Mass SpectrometryThionucleosides2'-deoxy-4'-thiocytidineAntineoplastic AgentsDeoxycytidineThionucleosides4′-thio-2′-deoxycytidineForced degradationHPLC validationImpurity and degradation product characterizationNSC 764276T-dCyd

Identifiers

PMID27661436
PMCPMC5063648

What OpenQuestion holds

Textmetadata
LicenceTDM
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.